Raleigh-based PRA announced a deal with biotechnology giant Amgen that calls for it to help Amgen develop generic versions of biotech drugs.
Financial terms of the deal, under which PRA will work with Amgen on Phase 3 clinical trials of all of its biosimilars, also known as biogenerics, weren't disclosed.
Biosimilars are biotech drugs that are similar to brand-name drugs. Because biotech drugs come from living cells and are complex to manufacture, however, clinical trials are required before they can be approved by U.S. regulators.
PRA has conducted numerous clinical trials for biosimilars involving more than 2,000 patients. The contract research organization has more than 4,400 employees, including 450 locally.
David Ranii has been a business reporter at The News & Observer since 1993. Over the years he has covered information technology, banking, insurance, the pharmaceutical and biotechnology industries, media businesses and real estate. Contact him at 919-829-4877 or